Pharmaceutical Product Development (PPDI) Reports Inline Q3 EPS of $0.32
More News related to PPDI
- PPD, Inc. (PPDI) Agrees to Acquire BioDuro
- PPD to Acquire BioDuro
- PPD, Inc. (PPDI) Announces Agreement with Janssen Pharmaceutica to Commercialize 2 Phase II-Ready Therapeutic Compounds
- PPD and Janssen Pharmaceutica Collaborate to Develop Compounds for Treatment of Irritable Bowel Syndrome and Bacterial Infections
- PPD (PPDI) Declares $0.15 Quarterly Dividend; 2.9% Yield
More News related to Earnings
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
Pharmaceutical Product Development (NASDAQ: PPDI) reports Q3 EPS of $0.32, inline with the analyst estimate of $0.32. Revenue for the quarter was $341.1 million, which compares to the estimate of $334.16 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
